New Data Presented at the American Diabetes Association’s 86th Scientific Sessions Suggest Amylin and Incretin Combination Therapy Could Become a Major Trend in Obesity Research
The American Diabetes Association’s (ADA) 86th Scientific Sessions, held June 5–8, 2026, in New Orleans, Louisiana, brought together more than 12,000 clinicians, researchers, pharmaceutical executives, and healthcare professionals to discuss the latest breakthroughs in diabetes, obesity, and metabolic disease.
As expected, obesity therapeutics were one of the dominant themes throughout the conference.
However, one presentation from Eli Lilly may end up being remembered as one of the most important obesity research updates of the entire meeting.
The Lilly-sponsored ADA poster 3082-LB evaluated eloralintide and tirzepatide separately and together in rats with diet-induced obesity. These are preclinical findings, not human results or evidence that the combination is approved. The published ADA abstract describes two weeks of co-administration, while the sponsor’s poster describes four weeks for that experiment. The numerical four-week figures below are attributed to the poster; the discrepancy should be resolved before treating the timing as settled. An abstract provides limited methodological detail.
At first glance, many observers focused on the weight-loss data.
After reviewing the ADA poster in detail, however, the most important takeaway may not have been the magnitude of weight reduction itself.
Instead, it may have been what the study reveals about where obesity treatment is heading next.
What Is Eloralintide?
Eloralintide (LY3841136) is a long-acting selective amylin receptor agonist currently being developed by Eli Lilly for obesity and metabolic disease.
Amylin is a naturally occurring peptide hormone that is co-secreted with insulin and plays an important role in:
- Satiety signaling
- Meal termination
- Regulation of food intake
- Energy balance
Unlike GLP-1 receptor agonists such as semaglutide or dual agonists such as tirzepatide, amylin receptor agonists target a different biological pathway involved in appetite regulation.
This distinction is one reason why pharmaceutical companies have become increasingly interested in combining amylin therapies with incretin therapies.
Rather than competing with GLP-1-based drugs, amylin agonists may potentially complement them.
The Most Interesting Aspect of Lilly’s ADA 2026 Study
The poster studied both simultaneous administration and an add-on design in a rat model.
Lilly took a different approach.
In addition to evaluating co-administration, researchers also tested an adjunctive treatment model.
Animals first received Tirzepatide alone.
Eloralintide was then added later.
At first glance this may seem like a minor design decision.
It is not.
In fact, this may be the single most important detail in the entire presentation.
Why?
The model was designed to investigate whether adding a second pathway after initial exposure changed outcomes in the animals. It does not establish a clinical approach for people.
- Rats received tirzepatide during an initial study period
- Researchers recorded body-weight changes
- Eloralintide was added in a separate study group
- Investigators compared outcomes across study groups
- The results apply to the experimental animal model
In the rat experiment, researchers explored whether adding eloralintide changed outcomes after tirzepatide exposure. This animal result does not establish what would happen in people or provide instructions for laboratory reference materials.
Research update, November 5, 2026: Since this rat poster, Lilly has reported a separate 48-week Phase 2b study of eloralintide and tirzepatide in adults with obesity or overweight and type 2 diabetes. See our Phase 2b research overview for the population, comparator and evidence limits. The clinical study and rat experiment are separate; the sponsor-reported findings do not establish approval. Later Phase 3 coformulation studies are registered, including AMPLIFY-1 and AMPLIFY-2; registration describes a study plan, not its results.
ADA 2026 Results: Eloralintide and Tirzepatide Produced Additive Effects
According to Lilly’s ADA poster, co-administration produced additive reductions in body weight in rats with diet-induced obesity. The animal study cannot determine human outcomes.
What changed after the rat poster? The ADA animal experiment is a mechanistic, preclinical finding. Lilly subsequently reported a distinct 48-week Phase 2b combination study in adults, and registrations now describe the Phase 3 AMPLIFY program. Those findings should not be combined into one effect-size estimate or treated as guidance for laboratory materials. Our eloralintide research guide provides clinical-study context; the dated trial index distinguishes studies, designs and registrations.
Simultaneous Administration Results
The sponsor’s poster reports the following after four weeks of co-administration. The published abstract describes two weeks, so the timing discrepancy remains unresolved:
- Eloralintide alone produced approximately 10% body-weight reduction
- Tirzepatide alone produced approximately 9% body-weight reduction
- The combination produced approximately 20% body-weight reduction
The combined response was substantially greater than either therapy alone.
While these are preclinical findings and should not be interpreted as human outcomes, the results support the hypothesis that amylin and incretin pathways may provide complementary biological effects.
The Adjunctive Treatment Data May Be Even More Important
The most intriguing section of the ADA presentation involved the add-on treatment model.
Researchers first administered Tirzepatide for two weeks before introducing Eloralintide.
The poster reported the following weight changes in the rat groups. These values are specific to the experimental design and do not establish a dose-response relationship in humans:
Tirzepatide Alone
Approximately 9% body-weight reduction
Tirzepatide + Low-Dose Eloralintide
Approximately 11% body-weight reduction
Tirzepatide + Mid-Dose Eloralintide
Approximately 15% body-weight reduction
Tirzepatide + High-Dose Eloralintide
Approximately 21% body-weight reduction
This finding suggests that activation of the amylin pathway continued producing additional effects even after Tirzepatide had already generated substantial weight reduction.
That observation could have important implications for future obesity treatment strategies.
More Than Weight Loss: Food Intake and Fat Mass Changes
The ADA 2026 poster also evaluated food intake and body composition.
Researchers observed:
- Greater reductions in daily food intake
- Prolonged suppression of food consumption
- Larger reductions in fat mass
Compared with either treatment alone, combination therapy appeared to produce more durable reductions in food intake over the course of treatment.
These findings suggest that the additive weight-loss effects may be driven, at least in part, by complementary effects on satiety and feeding behavior.
Why Big Pharma Is Suddenly Obsessed With Amylin Agonists
One of the biggest themes emerging from ADA 2026 is the growing industry-wide focus on amylin biology.
Just a few years ago, nearly every major obesity program centered around incretin pathways.
The progression looked like this:
First Generation
GLP-1 receptor agonists
Second Generation
Dual agonists such as Tirzepatide
Third Generation
Triple agonists such as Retatrutide
Today, however, many researchers believe the next evolution may involve combining incretin therapies with entirely different biological pathways.
Amylin is rapidly becoming one of the leading candidates.
The fact that both Eli Lilly and Novo Nordisk are investing heavily in amylin-based programs should not be ignored.
When the two largest obesity companies in the world independently move toward the same scientific conclusion, researchers pay attention.
Eloralintide vs Cagrilintide: Two Different Approaches to Amylin Biology
Cagrilintide helped establish amylin agonists as a serious category within obesity treatment.
Eloralintide represents a different approach.
Eloralintide was specifically designed as a selective amylin receptor agonist, potentially differentiating it from earlier compounds in the category.
While additional clinical data will be necessary to fully understand how these programs compare, the emergence of multiple large-scale pharmaceutical investments in amylin biology reinforces confidence in the pathway itself.
What ADA 2026 Means for Lilly’s Obesity Pipeline
Lilly already possesses one of the strongest obesity-development portfolios in the pharmaceutical industry.
Current programs include:
- Tirzepatide
- Retatrutide
- Eloralintide
- Multiple next-generation metabolic therapies
The ADA 2026 presentation suggests Lilly may be exploring a future where Eloralintide functions not simply as a standalone therapy but also as a combination partner.
Researchers are investigating separate questions about combination biology:
Eloralintide and tirzepatide research
or
Other potential combinations
These possibilities remain investigational.
The cited ADA poster evaluated eloralintide with tirzepatide in rats; it did not test a retatrutide combination. Separate studies are needed to assess each combination.
The Bigger Trend: Combination Therapy May Become the Future of Obesity Treatment
Perhaps the most important lesson from ADA 2026 is that obesity research is becoming increasingly sophisticated.
The field is gradually moving away from the search for a single “best” therapy.
Instead, researchers are beginning to explore how multiple biological systems can be targeted simultaneously.
This evolution mirrors what has occurred in:
- Oncology
- Cardiovascular medicine
- Diabetes management
In each case, combination therapy eventually became standard practice.
Obesity treatment may be entering a similar phase.
Final Thoughts
The Eloralintide and Tirzepatide presentation at the ADA 2026 Scientific Sessions did more than showcase encouraging preclinical data.
It provided a glimpse into how obesity treatment may evolve over the coming decade.
The additive effects observed in Lilly’s study were certainly noteworthy.
However, the most important signal may have been strategic rather than statistical.
Lilly appears to be investigating a future in which amylin receptor agonists are layered onto existing incretin therapies rather than replacing them.
If that vision ultimately proves successful in clinical development, ADA 2026 may be remembered as one of the earliest moments that signaled the rise of next-generation combination obesity therapy.
For clinicians, researchers, investors, and anyone following the rapidly evolving obesity landscape, that possibility may be the most important takeaway of all.